ClinicalTrials.gg
CompletedNCT06401941Updated May 7, 2024

Selected Lysosomal Enzyme Activities and the Oxidant-antioxidant Balance in Hyperbaric Oxygen Condition.

An interventional study of Hyperbaric Oxygen Therapy in Hyperbaric Oxygenation, Oxygen Toxicity and Antioxidants, sponsored by Nicolaus Copernicus University. Completed at 1 site in Poland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Nicolaus Copernicus University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 8 years after the study started (first participant enrolled Apr 2016, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the research project was to investigate the effects of hyperbaric oxygen (HBO) treatment on the redox equilibrium in individuals with different pathological conditions. Both hyperbaric oxygenation and the pathological condition are associated with redox imbalance (oxidative stress), however, HBO is successfully used in the treatment of chronic wounds, e.g., diabetic foot syndrome, as well as in sudden and acute hearing loss, e.g., acute acoustic trauma or idiopathic sudden sensorineural hearing loss.

Read the detailed description

The study involed in sudden sensorineural hearing loss (SSNHL) patients, individuals with difficult-to-heal skin wounds following mechanical injuries, and diabetic foot patients. HBO therapy, which involved inhalation of 100% oxygen at a pressure of 2.5 atm, consisted of 14-30 sessions depending on the clinical case. The study material was venous blood drawn three times: before and after the first session, and after the last HBO procedure. The following variables were evaluated: the concentrations of thiobarbituric acid reactive substances (TBARS), malondialdehyde (MDA) and conjugated dienes (CD) in plasma and erythrocytes, the activities of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx) in erythrocytes, as well as, blood counts.

02

Conditions studied

  • Hyperbaric Oxygenation
  • Oxygen Toxicity
  • Antioxidants
  • Oxidative Stress
03

In context

Lead sponsor

Nicolaus Copernicus University is the lead sponsor of 19 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed form for participation in the study

Exclusion criteria

Exclusion Criteria:

  • other pathological conditions (disorders, wounds, diseases)
  • bad feeling of the participant on the day of the study,
  • refraining from smoking, drinking alcohol, and the consumption of any dietary supplements that can affect the oxidant-antioxidant balance.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Patients

    Hyperbaric oxygen (HBO) therapy.

    Procedure: Hyperbaric Oxygen Therapy

  • No intervention
    Controls

    Healthy individuals that never treated with HBO therapy.

Interventions

  • ProcedureHyperbaric Oxygen Therapy

    HBO session includes three 20-minute inhalations of pure oxygen in a hyperbaric chamber utilizing specially fitted face masks for each patient. The session is conducted as follows: 10 minutes compression of up to 2.5 atm (0.25 MPa), inhalation of 100% oxygen for 20 minutes, a 5-minute break in the chamber without the mask (oxygen concentration up to 23%, constant temperature (room) and humidity), again 20 minutes inhalation of 100% oxygen, another 5-minute break (the same condition), the last 20 minutes inhalation of 100% oxygen, and finally a 10-minute decompression. The total duration of the session was 90 minutes.

    Also known as: HBO treatment, Hyperbaric Oxygenation

06

What researchers measure

Primary outcomes

  1. Thiobarbituric acid reactive substances (TBARS)

    Lipid peroxidation index represented by malondialdehyde (MDA), determined in plasma and erythrocytes.

    Time frame: Three days, three different condition measurements

  2. Malondialdehyde (MDA)

    Lipid peroxidation index; pure MDA determined using high-performance liquid chromatography in plasma and erythrocytes.

    Time frame: Three days, three different condition measurements

  3. Conjugated dienes (CD)

    Lipid peroxidation index, determined in plasma and erythrocytes.

    Time frame: Three days, three different condition measurements

  4. Catalase (CAT)

    Antioxidant enzyme, determined in erythrocytes.

    Time frame: Three days, three different condition measurements

  5. Superoxide dismutase (SOD)

    Antioxidant enzyme, determined in erythrocytes.

    Time frame: Three days, three different condition measurements

  6. Glutathione peroxidase (GPx)

    Antioxidant enzyme, determined in erythrocytes.

    Time frame: Three days, three different condition measurements

Secondary outcomes

  1. White blood cell count (WBC)

    Leukocytes found in peripheral blood with specyfication of their types: lymphocytes, monocytes, neutrophils, eosinophils, basophils.

    Time frame: Two days, two different condition measurements

  2. Red blood cell count (RBS)

    Erythrocytes found in peripheral blood.

    Time frame: Two days, two different condition measurements

  3. Hemoglobin (HGB)

    Mean concentration of hemoglobin in the blood.

    Time frame: Two days, two different condition measurements

  4. Hematocrit (HCT)

    The percentage of red blood cells in the blood.

    Time frame: Two days, two different condition measurements

  5. Mean corpuscular volume (MCV)

    Mean volume of erythrocytes in the blood.

    Time frame: Two days, two different condition measurements

  6. Mean corpuscular hemoglobin (MCH)

    Mean mass of hemoglobin in an erythrocyte.

    Time frame: Two days, two different condition measurements

  7. Mean corpuscular hemoglobin concentration (MCHC)

    MCH expressed in a unit of blood volume.

    Time frame: Two days, two different condition measurements

  8. Red cell distribution width (RDW)

    Differences in the volume and size of erythrocytes.

    Time frame: Two days, two different condition measurements

  9. Platelets (PLT)

    Thrombocytes found in peripheral blood.

    Time frame: Two days, two different condition measurements

  10. Plateletcrit (PCT)

    Volume occupied by platelets in the blood.

    Time frame: Two days, two different condition measurements

  11. Mean platelet volume (MPV)

    Mean volume of thrombocytes in the blood.

    Time frame: Two days, two different condition measurements

  12. Platelet distribution width (PDW)

    Measurement of platelet anisocytosis calculated from the distribution of individual platelet volumes.

    Time frame: Two days, two different condition measurements

07

Study locations

1 site
  • Department of Medical Biology and Biochemistry, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Karlowicza 24, 85-092 Bydgoszcz, Poland
    Bydgoszcz, Kujawsko-Pomorskie 85-092, Poland
08

References and documents

Individual participant data

Plan to share: No — There is no individual participant data (IPD) sharing plan.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Dec 2020, 56 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 7, 2024
StartActual
Apr 26, 2016
Primary completionActual
Dec 31, 2020
CompletionActual
Dec 31, 2020
Last update
May 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06401941
Lead sponsor
Nicolaus Copernicus University
Responsible party
Paweł Sutkowy (PhD, Assistant professor, Nicolaus Copernicus University) — Principal investigator
First posted
May 7, 2024
Start date
Apr 26, 2016
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020
Last update
May 7, 2024

Study contacts

Paweł Sutkowy, PhD
principal investigator · Department of Medical Biology and Biochemistry, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Karlowicza 24, 85-092 Bydgoszcz, Poland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion